Prognosis Research: A Strategic Initiative in Translational Pathways (PROGRESS)

Lead Research Organisation: University College London
Department Name: Epidemiology and Public Health

Abstract

Strategic importance A basic form of clinical enquiry involves characterising people with disease or illness at one time point and following them up to see whether and why they have progressed at another time point. Such prognosis research is important in understanding how to ?translate? new approaches to improving health from initial discovery, through phases of evaluation and, where appropriate, into clinical practice. Prognosis research should complement and add value to MRC strategic aims, relating to: genetics, biomarkers, wellbeing, exploitation of health records and population based data and translational research.

But numerous systematic reviews across different disease areas suggest that there is a gap between the promise of prognosis research and its ability to deliver. As a response to this we have developed a forthcoming series of 6 articles in BMJ/PloSMed which sets out a framework of prognosis research and makes recommendations.

Aim: The aim of the PROGRESS Partnership is to critically develop and systematically apply concepts, methods and recommendations (from the initial PROGRESS article series and elsewhere) across different disease areas in order to enhance the translational impact of prognosis research.

Partnership We will achieve this aim by establishing a new international consortium in translational prognosis research. Investigators in the Partnership (drawn from authors of the 6 article series) lead current prognosis research funding of #66 million. With MRC support the international Partnership will be established across disease areas and methodological disciplines.

Partnership workstreams The Partnership will deliver three inter-related, milestone-driven workstreams: I Enabling activities, through targeted workshops we seek to (a) advance methods development in stratified medicine, which seeks to target treatments at those patients who will benefit the most (b) improve the openness (?transparency?) with which prognosis research is reported in scientific papers, (c) identify opportunities for better research across clinical cohorts and (d) disseminate Partnership findings (knowledge transfer). II New research We will do new research, focussing on examples of where prognosis research is important in translation across our Partnership. We will both look backwards at published literature (knowledge synthesis) and forwards carrying out new analyses in our own clinical cohorts. These include novel opportunities in over 50,000 patients with different diseases: coronary disease; cancer, acute severe bleeding in trauma and childbirth and musculoskeletal disorders. III Training We will develop a range of taught course, higher degree and Fellowship opportunities to develop future national and international leaders in prognosis research.

Technical Summary

Strategic importance Prognosis research should be a basic science for translational research, clinical practice, personalised medicine and, with increasing periods of the lifecourse lived with chronic disease, for public health. Prognosis research should complement and add value to MRC strategic aims, principally those relating to: genetics, biomarkers, wellbeing, translational research and exploitation of health records and population based data.

But numerous systematic reviews across different disease areas suggest that there is a gap between the promise of prognosis research and its ability to deliver. Internationally there have been no initiatives bringing together prognosis research across early and late stages in translation, across different prognosis research questions, and across disease areas. In short, the field is fragmented. As a response to this we have developed a forthcoming series of 6 articles in BMJ/PloSMed which sets out a framework of prognosis research and makes recommendations.

Aim: The aim of the PROGRESS Partnership is to critically develop and systematically apply concepts, methods and recommendations (from the initial PROGRESS article series and elsewhere) across different disease areas in order to enhance the translational impact of prognosis research.

Partnership We will achieve this aim by establishing a new international consortium in translational prognosis research. Investigators in the Partnership (drawn from authors of the 6 article series) lead current prognosis research funding of #66m. With MRC support we will galvanise these resources with a Partnership across disease areas (cardiovascular, cancer, musculoskeletal, trauma and emergency medicine) and methodological disciplines (biostatistics, epidemiology, genetics, biomarkers, health services research).

Partnership workstreams The Partnership will break new ground in delivering three inter-related, milestone-driven workstreams: I Enabling and underpinning activities, through targeted workshops we will advance methods development in stratified medicine, ?transparency? standards in prognostic models, strategic direction across new and existing prognostic cohorts and knowledge transfer. II New research on translational exemplars involving new knowledge syntheses in stratified medicine (field synopses and high resolution systematic reviews), and new prospective analyses in our Partnership cohorts and trials. We will exploit novel opportunities in coronary disease (cohort with DNA and deep phenotyping n=5000); cancer (new translational DNA, plasma and tissue bioresource cohort of head and neck cancer patients, n=5000), acute severe haemorrhage trials in trauma (n=20,000), post-partum haemorrhage (n=15,000); musculoskeletal disorders n=7000 patients with repeat measures over 7 years. III boosting capability through training developing future national and international leaders in prognosis research through taught courses, PhD studentships, and Fellowships.

Publications

10 25 50

publication icon
Blackburn R (2018) Laboratory-Confirmed Respiratory Infections as Predictors of Hospital Admission for Myocardial Infarction and Stroke: Time-Series Analysis of English Data for 2004-2015. in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

 
Description Estimating excess 1-year mortality associated with the COVID-19
Geographic Reach National 
Policy Influence Type Citation in other policy documents
Impact We provide policy makers, researchers, and the public a simple model and an online tool for understanding excess mortality over 1 year from the COVID-19 pandemic, based on age, sex, and underlying condition-specific estimates. These results signal the need for sustained stringent suppression measures as well as sustained efforts to target those at highest risk because of underlying conditions with a range of preventive interventions. Countries should assess the overall (direct and indirect) effects of the pandemic on excess mortality.
 
Description Excess cancer deaths in COVID-19
Geographic Reach National 
Policy Influence Type Citation in other policy documents
Impact Our work on excess cancer deaths in COVID-19 has been in the media continuously since March, now published in Lancet, and has been included in SAGE priorities and informed several policy changes including the early focus on 'indirect' deaths, the weekly reporting of excess deaths by the Office for National Statistics, and approaches to understanding vulnerable patients. A number of outlets featured the study outcomes including BBC Panorama's 'Britain's Cancer Crisis', the Independent's 'Cancer is the other 'big C' we can't afford to push aside' and Macmillian Cancer Support's 'The Forgotten 'C'? The impact of Covid-19 on cancer care'. https://www.bbc.co.uk/programmes/m000kqzv https://www.independent.co.uk/voices/coronavirus-nhs-cancer-testing-death-toll-illness-symptoms-check-gp-a9492161.html https://www.macmillan.org.uk/assets/forgotten-c-impact-of-covid-19-on-cancer-care.pdf
 
Description OurRisk.CoV risk calculator
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in other policy documents
Impact Our OurRisk.CoV risk calculator (available here: http://covid19-phenomics.org/PrototypeOurRiskCoV.html) has had 1.3 million pageviews from 636K users across the world (e.g. 21% of users from the United States). The risk calculator is also on the BHF website (https://www.bhf.org.uk/informationsupport/heart-matters-magazine/news/coronavirus-and-your-health/how-to-find-out-your-risk-when-it-comes-to-coronavirus)
URL https://covid19-phenomics.org/PrototypeOurRiskCoV.html
 
Description Accelerator Award
Amount £1,000,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2019 
End 03/2024
 
Description Tackling multimorbidity at scale: Understanding disease clusters, determinants & biological pathways
Amount £2,900,000 (GBP)
Funding ID MR/V033867/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2021 
End 03/2024
 
Description 4C Cost-effectiveness Collaboration 
Organisation University of York
Department Centre for Health Economics (CHE)
Country United Kingdom 
Sector Academic/University 
PI Contribution Expertise in Clinical Epidemiology Grant writing Wriring of journal articles
Collaborator Contribution Health economics, evidence synthesis, decision modelling Grant writing Wriring of journal articles
Impact To follow
 
Description Akcea Therapeutics 
Organisation Akcea Therapeutics
Country United States 
Sector Private 
PI Contribution TBC
Collaborator Contribution TBC
Impact Not yet.
Start Year 2018
 
Description Astra Zeneca Cardiovascular Renal and Metabolic disorder (£0.5M) 
Organisation AstraZeneca
Department Astra Zeneca
Country United States 
Sector Private 
PI Contribution As PI we will determine aetiologic relations among these commonly occurring conditions and the impact this may have on the design and interpretation of major trials.
Collaborator Contribution Collaboration between UCL and Astra Zeneca for a study on cardiovascular renal and metabolic disorders: 2019-2020, £0.5M
Impact Meetings and engagement activities have taken place to maximse scientific and societal benefits.
Start Year 2019
 
Description British Heart Foundation-HDR UK National Cardiovascular Data Science Centre 
Organisation British Heart Foundation (BHF)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution As member of Scientific Steering Group gave invited talk at workshop (phenomics) and advised on priorities
Collaborator Contribution £10M
Impact Academic, research and clinical outputs
Start Year 2019
 
Description Computing eInfrastructure for genomic and imaging data (eMEDLAB) 
Organisation Medical Research Council (MRC)
Department MRC Medical Bioinformatics Infrastructure Grant
Country United Kingdom 
Sector Academic/University 
PI Contribution Co-PI
Collaborator Contribution MRC £9M
Impact academic, research and clinical outputs
Start Year 2015
 
Description Digital Innovation Hub DATA CAN 
Organisation Health Data Research UK
Country United Kingdom 
Sector Private 
PI Contribution I contributed to the engagement of industry partners including IQVIA (2019-)
Collaborator Contribution IQVIA
Impact As part of the Digital Innovation Hub process I contributed to the engagement of industry partners including IQVIA
Start Year 2019
 
Description European Innovative Medicines Initiative-2 Horizon 2020 Big Data for Better Outcomes BigData@Heart 
Organisation European Commission
Department Horizon 2020
Country European Union (EU) 
Sector Public 
PI Contribution I am the PI on this project and have provided scientific and management leadership
Collaborator Contribution €9m H2020, €9m Industry
Impact Academic and research outputs
Start Year 2017
 
Description European leverage of health records and omics for drug development: Innovative Medicines Initiative 2 'Big Data for Better Outcomes' (Servier, Bayer, Novartis, Vifor, Actelion and Somalogic) 
Organisation Servier Laboratories
Country France 
Sector Private 
PI Contribution I lead two work packages (informatics platform and omics enrichment) and sit on the five-member Executive of this 2017-2022 initiative seeking to tackle unmet need in heart failure, atrial fibrillation and acute coronary syndromes
Collaborator Contribution European leverage of health records and omics for drug development: Innovative Medicines Initiative 2 'Big Data for Better Outcomes'  (£9m from Horizon 2020 + £9m in kind from Servier, Bayer, Novartis, Vifor, Actelion and Somalogic).
Impact TBC
Start Year 2017
 
Description Farr Institute of Health Informatics Research 
Organisation Farr Institute of Health Informatics Research
Country United Kingdom 
Sector Academic/University 
PI Contribution Grant writing Developing infrastructure Capacity Building Public and Patient Engagement Research
Collaborator Contribution Grant writing Developing infrastructure Capacity Building Public and Patient Engagement Research
Impact None at present
Start Year 2013
 
Description Farr Institute of Health Informatics Research 
Organisation Farr Institute of Health Informatics Research
Country United Kingdom 
Sector Academic/University 
PI Contribution Grant writing Developing infrastructure Capacity Building Public and Patient Engagement Research
Collaborator Contribution Grant writing Developing infrastructure Capacity Building Public and Patient Engagement Research
Impact None at present
Start Year 2013
 
Description Farr Institute of Health Informatics Research 
Organisation Farr Institute of Health Informatics Research
Country United Kingdom 
Sector Academic/University 
PI Contribution Grant writing Developing infrastructure Capacity Building Public and Patient Engagement Research
Collaborator Contribution Grant writing Developing infrastructure Capacity Building Public and Patient Engagement Research
Impact None at present
Start Year 2013
 
Description Farr Institute of Health Informatics Research, London 
Organisation London School of Hygiene and Tropical Medicine (LSHTM)
Country United Kingdom 
Sector Academic/University 
PI Contribution Grant writing Research Writing of peer-reviewed papers Organisation of workshops, seminars, PhD programme and other training opportunities Infrastructure development
Collaborator Contribution Grant writing Research Writing of peer-reviewed papers Organisation of workshops, seminars, PhD programme and other training opportunities Infrastructure development
Impact to follow
Start Year 2012
 
Description Farr Institute of Health Informatics Research, London 
Organisation Public Health England
Country United Kingdom 
Sector Public 
PI Contribution Grant writing Research Writing of peer-reviewed papers Organisation of workshops, seminars, PhD programme and other training opportunities Infrastructure development
Collaborator Contribution Grant writing Research Writing of peer-reviewed papers Organisation of workshops, seminars, PhD programme and other training opportunities Infrastructure development
Impact to follow
Start Year 2012
 
Description Farr Institute of Health Informatics Research, London 
Organisation Queen Mary University of London
Country United Kingdom 
Sector Academic/University 
PI Contribution Grant writing Research Writing of peer-reviewed papers Organisation of workshops, seminars, PhD programme and other training opportunities Infrastructure development
Collaborator Contribution Grant writing Research Writing of peer-reviewed papers Organisation of workshops, seminars, PhD programme and other training opportunities Infrastructure development
Impact to follow
Start Year 2012
 
Description Farr Institute of Health Informatics Research, London 
Organisation UCL Partners
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Grant writing Research Writing of peer-reviewed papers Organisation of workshops, seminars, PhD programme and other training opportunities Infrastructure development
Collaborator Contribution Grant writing Research Writing of peer-reviewed papers Organisation of workshops, seminars, PhD programme and other training opportunities Infrastructure development
Impact to follow
Start Year 2012
 
Description Health Data Research UK 
Organisation Health Data Research UK
Country United Kingdom 
Sector Private 
PI Contribution Inaugural Research Director
Collaborator Contribution £120m 2018-2023, with responsibility for London £10m
Impact Health Data Research in the UK
Start Year 2018
 
Description HiGODS, Cross-cutting (Healthcare Informatics, Genomics/omics, Data Science) 
Organisation National Institute for Health Research
Department UCLH/UCL Biomedical Research Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution I have provided leadership contribution as Director, Healthcare Informatics, Genomics/omics, Data Science from 2016
Collaborator Contribution tbc
Impact Meetings, Publications, Engagement Activities, Education, Policy,
Start Year 2016
 
Description NIHR UCLH/UCL Biomedical Research Centre (Informatics) 
Organisation National Institute for Health Research
Department UCLH/UCL Biomedical Research Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution I have been providing leadership vision and direction as the BRC Executive member since 2017
Collaborator Contribution BRC £110m, £3m for theme 2017-2022
Impact Publications, Meetings, Engagement Activities, Reports, Recommendation to policy
Start Year 2017
 
Description OneLondon LHCRE 
Organisation NHS England
Country United Kingdom 
Sector Public 
PI Contribution Academic and Research Leadership in bringing OnLondon LHCRE together with Luke Readman
Collaborator Contribution £0.9M
Impact Academic, research and clinical outputs
Start Year 2017
 
Description PROGRESS (Prognosis Research Strategy) Partnership (2011-2016 MRC £800k 
Organisation Keele University
Department Research Institute for Primary Care and Health Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution We developed a series of articles which sets out a framework of prognosis research and makes recommendations. Apart from these core papers, we have promoted the PROGRESS framework of prognosis research in several auxiliary papers and research exemplars from our ongoing population research. We have collaborated with other partner for writing grants, and currently plan to apply for an MRC Methodology research programme grant to continue our collaborations for developing new methods in the prognosis research area. We have also organised several workshops and short courses and presented our partnership in various international meetings and collaborations.
Collaborator Contribution Our partners have contributed in all areas of this partnership including writing and preparation of the core papers and research exemplars, promoting the the PROGRESS framework in various meetings and research collaborations, writing grants (both methodological and translational), and organising and presenting in workshops and short courses that we developed.
Impact MRC grant G0902393 16 manuscripts published 2 International three-day courses (PROGRESS Summer Course in Prognosis Research 2013 & 2014) Several workshops about prognosis research, use of longitudinal data, clinical cohorts, Stratified Medicine, diagnosis versus prognosis Monthly teleconferences for discussing ideas and 3 overall PROGRESS Research meetings so far (last one Oct 2014 at Farr Institute, London)
Start Year 2011
 
Description PROGRESS (Prognosis Research Strategy) Partnership (2011-2016 MRC £800k 
Organisation London School of Hygiene and Tropical Medicine (LSHTM)
Department Faculty of Epidemiology and Population Health
Country United Kingdom 
Sector Academic/University 
PI Contribution We developed a series of articles which sets out a framework of prognosis research and makes recommendations. Apart from these core papers, we have promoted the PROGRESS framework of prognosis research in several auxiliary papers and research exemplars from our ongoing population research. We have collaborated with other partner for writing grants, and currently plan to apply for an MRC Methodology research programme grant to continue our collaborations for developing new methods in the prognosis research area. We have also organised several workshops and short courses and presented our partnership in various international meetings and collaborations.
Collaborator Contribution Our partners have contributed in all areas of this partnership including writing and preparation of the core papers and research exemplars, promoting the the PROGRESS framework in various meetings and research collaborations, writing grants (both methodological and translational), and organising and presenting in workshops and short courses that we developed.
Impact MRC grant G0902393 16 manuscripts published 2 International three-day courses (PROGRESS Summer Course in Prognosis Research 2013 & 2014) Several workshops about prognosis research, use of longitudinal data, clinical cohorts, Stratified Medicine, diagnosis versus prognosis Monthly teleconferences for discussing ideas and 3 overall PROGRESS Research meetings so far (last one Oct 2014 at Farr Institute, London)
Start Year 2011
 
Description PROGRESS (Prognosis Research Strategy) Partnership (2011-2016 MRC £800k 
Organisation Queen Mary University of London
Department Barts and The London School of Medicine and Dentistry
Country United Kingdom 
Sector Academic/University 
PI Contribution We developed a series of articles which sets out a framework of prognosis research and makes recommendations. Apart from these core papers, we have promoted the PROGRESS framework of prognosis research in several auxiliary papers and research exemplars from our ongoing population research. We have collaborated with other partner for writing grants, and currently plan to apply for an MRC Methodology research programme grant to continue our collaborations for developing new methods in the prognosis research area. We have also organised several workshops and short courses and presented our partnership in various international meetings and collaborations.
Collaborator Contribution Our partners have contributed in all areas of this partnership including writing and preparation of the core papers and research exemplars, promoting the the PROGRESS framework in various meetings and research collaborations, writing grants (both methodological and translational), and organising and presenting in workshops and short courses that we developed.
Impact MRC grant G0902393 16 manuscripts published 2 International three-day courses (PROGRESS Summer Course in Prognosis Research 2013 & 2014) Several workshops about prognosis research, use of longitudinal data, clinical cohorts, Stratified Medicine, diagnosis versus prognosis Monthly teleconferences for discussing ideas and 3 overall PROGRESS Research meetings so far (last one Oct 2014 at Farr Institute, London)
Start Year 2011
 
Description PROGRESS (Prognosis Research Strategy) Partnership (2011-2016 MRC £800k 
Organisation University College London
Department Research Department of Epidemiology and Public Health
Country United Kingdom 
Sector Academic/University 
PI Contribution We developed a series of articles which sets out a framework of prognosis research and makes recommendations. Apart from these core papers, we have promoted the PROGRESS framework of prognosis research in several auxiliary papers and research exemplars from our ongoing population research. We have collaborated with other partner for writing grants, and currently plan to apply for an MRC Methodology research programme grant to continue our collaborations for developing new methods in the prognosis research area. We have also organised several workshops and short courses and presented our partnership in various international meetings and collaborations.
Collaborator Contribution Our partners have contributed in all areas of this partnership including writing and preparation of the core papers and research exemplars, promoting the the PROGRESS framework in various meetings and research collaborations, writing grants (both methodological and translational), and organising and presenting in workshops and short courses that we developed.
Impact MRC grant G0902393 16 manuscripts published 2 International three-day courses (PROGRESS Summer Course in Prognosis Research 2013 & 2014) Several workshops about prognosis research, use of longitudinal data, clinical cohorts, Stratified Medicine, diagnosis versus prognosis Monthly teleconferences for discussing ideas and 3 overall PROGRESS Research meetings so far (last one Oct 2014 at Farr Institute, London)
Start Year 2011
 
Description PROGRESS (Prognosis Research Strategy) Partnership (2011-2016 MRC £800k 
Organisation University of Birmingham
Department Department of Public Health, Epidemiology & Biostatistics (PHEB)
Country United Kingdom 
Sector Academic/University 
PI Contribution We developed a series of articles which sets out a framework of prognosis research and makes recommendations. Apart from these core papers, we have promoted the PROGRESS framework of prognosis research in several auxiliary papers and research exemplars from our ongoing population research. We have collaborated with other partner for writing grants, and currently plan to apply for an MRC Methodology research programme grant to continue our collaborations for developing new methods in the prognosis research area. We have also organised several workshops and short courses and presented our partnership in various international meetings and collaborations.
Collaborator Contribution Our partners have contributed in all areas of this partnership including writing and preparation of the core papers and research exemplars, promoting the the PROGRESS framework in various meetings and research collaborations, writing grants (both methodological and translational), and organising and presenting in workshops and short courses that we developed.
Impact MRC grant G0902393 16 manuscripts published 2 International three-day courses (PROGRESS Summer Course in Prognosis Research 2013 & 2014) Several workshops about prognosis research, use of longitudinal data, clinical cohorts, Stratified Medicine, diagnosis versus prognosis Monthly teleconferences for discussing ideas and 3 overall PROGRESS Research meetings so far (last one Oct 2014 at Farr Institute, London)
Start Year 2011
 
Description PROGRESS (Prognosis Research Strategy) Partnership (2011-2016 MRC £800k 
Organisation University of Oxford
Department Centre for Statistics in Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution We developed a series of articles which sets out a framework of prognosis research and makes recommendations. Apart from these core papers, we have promoted the PROGRESS framework of prognosis research in several auxiliary papers and research exemplars from our ongoing population research. We have collaborated with other partner for writing grants, and currently plan to apply for an MRC Methodology research programme grant to continue our collaborations for developing new methods in the prognosis research area. We have also organised several workshops and short courses and presented our partnership in various international meetings and collaborations.
Collaborator Contribution Our partners have contributed in all areas of this partnership including writing and preparation of the core papers and research exemplars, promoting the the PROGRESS framework in various meetings and research collaborations, writing grants (both methodological and translational), and organising and presenting in workshops and short courses that we developed.
Impact MRC grant G0902393 16 manuscripts published 2 International three-day courses (PROGRESS Summer Course in Prognosis Research 2013 & 2014) Several workshops about prognosis research, use of longitudinal data, clinical cohorts, Stratified Medicine, diagnosis versus prognosis Monthly teleconferences for discussing ideas and 3 overall PROGRESS Research meetings so far (last one Oct 2014 at Farr Institute, London)
Start Year 2011
 
Description UCL Institute of Health Informatics 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Inaugural Director
Collaborator Contribution Current 5 year budget £33m
Impact Academic and Research
Start Year 2014
 
Description UK BIobank 
Organisation UK Biobank
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Cardiac outcomes working group
Collaborator Contribution Using research data to validate electronic health record data
Impact Papers in preparation
Start Year 2010
 
Description Article on the daily mail on published research 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Daily mail newspaper report on research: "Weight gain risk is at its greatest from the ages of 18 to 34... and the chances of becoming obese DECREASE in middle, study suggests"
Year(s) Of Engagement Activity 2021
URL https://www.dailymail.co.uk/health/article-9953055/Weight-gain-risk-greatest-ages-18-34-study-sugges...
 
Description Multiple media mentions of excess cancer deaths in COVID-19 study 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Our work on excess cancer deaths in COVID-19 has been in the media continuously since March, now published in Lancet, and has been included in SAGE priorities and informed several policy changes including the early focus on 'indirect' deaths, the weekly reporting of excess deaths by the Office for National Statistics, and approaches to understanding vulnerable patients.

A number of outlets featured the study outcomes including BBC Panorama's 'Britain's Cancer Crisis', the Independent's 'Cancer is the other 'big C' we can't afford to push aside' and Macmillian Cancer Support's 'The Forgotten 'C'? The impact of Covid-19 on cancer care'.

https://www.bbc.co.uk/programmes/m000kqzv
https://www.independent.co.uk/voices/coronavirus-nhs-cancer-testing-death-toll-illness-symptoms-check-gp-a9492161.html
https://www.macmillan.org.uk/assets/forgotten-c-impact-of-covid-19-on-cancer-care.pdf
Year(s) Of Engagement Activity 2020
 
Description OurRisk.CoV risk calculator 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Our OurRisk.CoV risk calculator (available here: http://covid19-phenomics.org/PrototypeOurRiskCoV.html) has had 1.3 million pageviews from 636K users across the world (e.g. 21% of users from the United States). The risk calculator is also on the BHF website (https://www.bhf.org.uk/informationsupport/heart-matters-magazine/news/coronavirus-and-your-health/how-to-find-out-your-risk-when-it-comes-to-coronavirus)
Year(s) Of Engagement Activity 2020
URL https://covid19-phenomics.org/PrototypeOurRiskCoV.html
 
Description Talk given to HDR UK North and NICE Collaborative Workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Invited to give talk titled ' A prognostic atlas for clinical practice guidelines' given to researchers, academics and other audience at the workshop.
Year(s) Of Engagement Activity 2021